Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

Fertility and Sterility

Volumn 67, Issue 5, 1997, Pages 917-922

  Albano, Carola ^a   Riethmüller Winzen, Hilde ^a,b   Smitz, Johan ^a   Van Steirteghem, André ^a   Camus, Michel ^a   Devroey, Paul ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^b Asta Medical   (Germany)

Author keywords

Controlled ovarian hyperstimulation; GnRH antagonist; in vitro fertilization; intracytoplasmic sperm injection; LH surge

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GONADOTROPIN RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL;

EID: 0342602067     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)81407-0     Document Type: Article

References (21)

1. Frydman R, Cornel C, de Ziegler D, Taïeb J, Spitz IM, Bouchard P. Spontaneous luteinizing hormone surges can be reliably prevented by timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase. Hum Reprod 1992;7:930-3.
2. Leroy I, d'Acremont MF, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril 1994;62: 461-7.
3. Frydman R, Cornel C, de Ziegler D, Taïeb J, Spitz IM, Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril 1991;56:923-7.
4. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-91.
5. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taïeb J, Selva J, et al. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 1994;62:468-76.
6. Olivennes F, Fanchin R, Bouchard P, Taïeb J, Selva J, Frydman R. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum Reprod 1995;10:1382-6.
7. Reissmann TH, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Scally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995;10:1974-81.
8. Smitz J, Van Den Abbeel E, Bollen N, Camus M, Devroey P, Tournaye H, et al. The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in vitro fertilization outcome in normo-ovulatory women. Hum Reprod 1992;7:1098-102.
9. 2 medium for human in-vitro fertilization performance. Hum Reprod 1994;9:1915-9.
10. Van Steirteghem AC, Liu J, Joris H, Nagy Z, Janssenswillen C, Tournaye H, et al. Higher success rate by intracytoplasmatic sperm injection than by subzonal insemination. Report of a second series of 300 consecutive treatment cycles. Hum Reprod 1993;8:1055-60.
11. Van Steirteghem AC, Nagy Z, Joris H, Liu J, Staessen C, Smitz J, et al. High fertilization and implantation rates after intracytoplasmatic sperm injection. Hum Reprod 1993;8:1061-6.
12. Van Steirteghem AC, Van der Elst J, Van Den Abbeel E, Joris H, Camus M, Devroey P. Cryopreservation of supernumerary multicellular human embryos obtained after intracytoplasmatic sperm injection. Fertil Steril 1994;62:775-80.
13. Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Wellington L, Rivier J, et al. The gonadotrophin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol 1991;165:1811-7.
14. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF and GIFT. Hum Reprod 1988;3:585-90.
15. Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human FSH (Org 32489) combined with various GnRH agonist regimens. Hum Reprod 1994;9:1064-9.
16. Smitz J, Devroey P, Camus M, Van Steirteghem, AC. Management of failed cycles in an IVF/GIFT program with the combination of a GnRH analog and HMG. Hum Reprod 1987;2:309-14.
17. Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, et al. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin releasing hormone. J Clin Endocrinol Metab 1987;64:980-5.
18. Pieper D, Richards J, Marshall JC. Ovarian gonadotropin-releasing hormone (GnRH) receptors: characterization, distribution and induction by GnRH. Endocrinology 1981; 108:1148-55.
19. Latouche J, Crumeyrolles-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedars L, et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by an autoradiographic study. Endocrinology 1989;125:1739-41.
20. Clayton RN, Harwood JP, Catt KJ. Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production. Nature 1979;282:90-2.
21. Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992;7:1225-9.